A Phase 1, Open-Label, Single-Dose, Pharmacokinetic and Safety Study of E7080 (24 mg) Administered to Subjects With Mild, Moderate, and Severe Renal Impairment and to Healthy Subjects
Public ClinicalTrials.gov record NCT02199379. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this multicenter, open-label, non-randomized, single, oral dose, sequential-cohort study was to determine pharmacokinetics and safety of lenvatinib (24 mg) administered to healthy subjects and to subjects with renal impairment.
Study identification
- NCT ID
- NCT02199379
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 26 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 79 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2011
- Primary completion
- Sep 30, 2012
- Completion
- Sep 30, 2012
- Last update posted
- Apr 13, 2015
2011 – 2012
United States locations
- U.S. sites
- 3
- U.S. states
- 3
- U.S. cities
- 3
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Orlando | Florida | 32809 | — |
| Not listed | Minneapolis | Minnesota | 55404 | — |
| Not listed | Knoxville | Tennessee | 37920 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Renal Impairment trials
Other public records listing Renal Impairment. Sorted by last update posted; newest first. Not a recommendation.
- NCT07426380: A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function Active, not recruiting
- NCT07559396: A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease Recruiting
- NCT07315360: A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function Recruiting
- NCT06911320: Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function Recruiting
- NCT07348237: A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006) Recruiting
- NCT07017933: Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02199379, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 13, 2015 · Synced Sep 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02199379 live on ClinicalTrials.gov.